Blog

Talha Badar: AML-BFM Study Group Recommendations on Pediatric Therapy-Related AML

Talha Badar/X

Jun 12, 2025, 10:49

Talha Badar: AML-BFM Study Group Recommendations on Pediatric Therapy-Related AML

Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X:

“Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

10 years OS post allo-HCT in recent decade up to 50% +/- 10%. Adverse cytogenetics, previous ionizing radiation (>35 Gy), and latency ≤1 year were identified as the strongest poor prognosticators. “

Title: Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

Authors: Stephanie Sendker, Markus Schneider, Evangelia Antoniou, Daniel Neumann, Naghmeh Niktoreh, Uta Dirksen, Nils von Neuhoff, Ursula Creutzig, Dirk Reinhardt, Katharina Waack

Read Full Article.

AML-BFM

Also read “Key Insights by Talha Badar from ASCO25” on OncoDaily.

Talha Badar

cancer Daniel Neumann Dirk Reinhardt Evangelia Antoniou Katharina Waack Markus Schneider Naghmeh Niktoreh Nils von Neuhoff OncoDaily Oncology Stephanie Sendker Talha Badar Ursula Creutzig Uta Dirksen

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening

Inside ASCO25 Exhibition - Who did it the best?

Douglas Flora: Fighting Cancer with Heart